Adial's Radical Reinvention: New Blood, New Money, New Mission

GLEN ALLEN, VA – June 16, 2026 – Adial Pharmaceuticals has effectively hit the reset button. In a series of decisive moves, the biopharmaceutical company has completed a business combination with Azora Therapeutics, installed Azora’s founders into its top leadership ranks, and simultaneously closed a $32 million financing round. This trifecta of corporate actions signals more than just a new chapter; it represents a fundamental reinvention of the company, shifting its strategic core from addiction treatments to the competitive, high-need market of inflammatory bowel disease.

For a company historically defined by its pursuit of a treatment for Alcohol Use Disorder, this pivot is a dramatic and deliberate maneuver. The successful capital raise and recruitment of seasoned executives are not merely line items in a press release; they are the foundational pillars of Adial’s new corporate strategy, designed to propel a promising new asset through the unforgiving gauntlet of clinical development.

A Strategic Overhaul: From Addiction to Inflammation

Until this month, Adial Pharmaceuticals was primarily known for its lead candidate, AD04, a genetically targeted therapeutic for Alcohol Use Disorder. While the company continues to support this legacy program, the acquisition of the private firm Azora Therapeutics has unequivocally shifted the spotlight. Adial is now a company with a new primary mission: conquering ulcerative colitis (UC).

The centerpiece of this new mission is AT177, a proprietary, colon-targeted oral drug candidate designed to treat UC. By acquiring Azora, Adial not only gained the intellectual property for AT177 but also absorbed the very team that conceived of and developed it. This move transforms Adial from a single-focus entity into a company with a diversified, albeit re-centered, pipeline. The strategic rationale is clear: pivot toward a program with a validated biological mechanism, a potentially superior safety profile, and the backing of specialist investors who see a path to market leadership.

This strategic redirection is a calculated risk. The ulcerative colitis market is crowded and fiercely competitive, but it is also a multi-billion dollar space where significant unmet medical needs persist. Many patients fail to respond to existing therapies or suffer from significant side effects, creating a clear opportunity for a novel treatment that can offer efficacy without systemic toxicity.

New Leadership, New Capital: Fueling the AT177 Engine

Any corporate transformation is only as credible as the people and capital driving it. On this front, Adial has made a compelling case. The company has appointed Matthew Davidson, Ph.D., as its new Chief Development Officer and Julie Saiki, Ph.D., as Executive Vice President of Strategy. These are not just new hires; they are the co-founders of Azora and the architects of the AT177 program.

Dr. Davidson brings a formidable track record in biotech leadership. Prior to co-founding Azora, he founded Verrica Pharmaceuticals, where he invented its core technology and guided the company through pivotal Phase 3 trials, ultimately leading to the first FDA-approved drug for molluscum contagiosum. Dr. Saiki’s involvement is even more personal; her own experience with refractory ulcerative colitis led her to investigate and validate the clinical potential of indigo naturalis, the botanical precursor that inspired AT177's development, in a trial at Stanford University.

To secure this critical expertise, Adial granted both executives substantial inducement awards of restricted stock units and options, a move made outside of standard equity plans under a specific Nasdaq rule reserved for material new hires. This underscores the company’s belief that their leadership is indispensable to AT177’s success.

Bolstering this new leadership is a significant infusion of capital. The company announced the closing of the first $32 million tranche of a private placement that could reach up to $64 million. The financing was led by Coastlands Capital and saw participation from a syndicate of respected biotech specialist funds, including Kern Capital, Boxer Capital Management, and Stonepine Capital Management. This roster of investors provides a powerful external validation of Adial's new direction.

Jay Kern, Founder and General Partner of Kern Capital, one of the lead investors, articulated the sentiment, stating, “Kern Capital focuses on differentiated life sciences programs with outstanding management teams and the potential to become market leaders within their indication, all of which we see at Adial. AT177 is a compelling opportunity, and Matt and Julie are exactly the right executives to help advance it.”

Targeting a Crowded Market: The Promise of AT177

AT177 enters a field dominated by biologics, JAK inhibitors, and other systemic therapies. Its strategic advantage lies in its design. The drug is a colon-targeted aryl hydrocarbon receptor (AhR) agonist, a prodrug of indirubin, which is the most potent AhR agonist found in the clinically effective botanical indigo naturalis.

The key innovation is its delivery mechanism. AT177 is engineered for “exquisite gut restriction,” meaning it activates the immune-balancing AhR pathway directly within the inflamed colonic tissue while minimizing absorption into the bloodstream. This localized action is intended to provide therapeutic benefit without the risks of systemic immunosuppression and other side effects that plague many current UC treatments. By restoring mucosal immune homeostasis at the site of the disease, AT177 aims to offer a best-in-class safety profile, a critical differentiator for a chronic condition requiring long-term therapy.

While the science is promising, the path forward is one of meticulous execution. The new capital is earmarked to advance AT177 through IND-enabling studies and into Phase 1 clinical trials, with an Investigational New Drug (IND) application targeted for 2027. These early studies will be crucial in demonstrating that the drug's elegant design translates into a safe and effective treatment for patients.

The Road Ahead: Financing a New Future

The initial $32 million provides Adial with the necessary runway to reach its next set of critical value-inflection points. The structure of the financing, with a potential second $32 million tranche, provides a clear roadmap for continued development. This second tranche is likely contingent on the successful achievement of key milestones, such as the IND filing or the first dosing of a patient in a clinical trial, aligning investor capital with tangible progress.

This structured financing de-risks the path forward and ensures the company is capitalized to move AT177 through its early clinical stages efficiently. While the company’s focus has clearly shifted, it has not entirely abandoned its past. Adial continues to advance its legacy AD04 program, recently filing a new patent and preparing for a Phase 3 trial. This dual-track approach preserves the value of its existing asset while dedicating the majority of its strategic momentum to its new, and potentially transformative, lead program. For Adial Pharmaceuticals, the future is now firmly rooted in the gut, backed by the capital and expertise to see if AT177 can deliver on its considerable promise.